Kimberly-Clark Prepares EU Remedies Ahead of Sept. 29 Deadline in $40 Billion Kenvue Deal

Kimberly-Clark is preparing concessions, potentially including asset sales, to address European Commission antitrust concerns over its proposed $40 billion acquisition of Kenvue, according to people familiar with the matter cited by Reuters, as reported by Yahoo Finance. The reporting describes remedies being prepared rather than a confirmed formal submission, with the European Commission's preliminary review scheduled to end on September 29.

EU Review Timeline and the Sept. 29 Deadline

The Commission opened its review after the transaction was formally notified on August 25, according to metissue.com. The case filing covers Kimberly-Clark's proposed acquisition of sole control of Kenvue and identifies overlapping activities in areas including feminine hygiene, alongside Kenvue's broader consumer-health portfolio.

According to sources cited by tissueonlinenorthamerica.com and metissue.com, the Commission was expected to formally communicate its competition concerns to Kimberly-Clark during the week of the report. That communication would help determine whether the company submits concessions during the preliminary, or Phase I, review, which ends September 29, or whether the case moves to a more in-depth investigation that could last approximately four months. Neither outlet's sources identified the specific assets that could be involved or the precise competition concerns the Commission has raised.

Remedies Still Undefined

Reuters reporting carried by metissue.com states that the concessions being prepared could include asset sales, but as of the report neither the assets potentially involved nor the specific EU competition concerns had been publicly identified. The European Commission declined to comment when contacted, and Kimberly-Clark and Kenvue did not respond to emailed requests for comment, per tissueonlinenorthamerica.com.

Other Regulatory Approvals Already Secured

The EU review is one piece of a broader multi-jurisdiction approval process. Australia's competition regulator, the ACCC, cleared the deal earlier in September on condition that Kimberly-Clark divest Kenvue's Carefree and Stayfree period-care brands in that country, according to tissueonlinenorthamerica.com and metissue.com. The ACCC said the divestiture was required to address competition concerns in the period care market, where Kimberly-Clark and Kenvue are two of the three major suppliers.

The deal also received conditional approval in South Africa the prior month, per both outlets. In Brazil, Kenvue agreed in August to sell its feminine-care business, including the Carefree, Sempre Livre and o.b. brands plus related manufacturing equipment, to Essity for $284 million, subject to Brazilian regulatory approval and completion of the Kimberly-Clark transaction. Competition-law publication MLex, as cited by metissue.com, reported that Kimberly-Clark and Kenvue are seeking Brazilian clearance without additional remedies, arguing the Essity sale removes the deal's only potential horizontal overlap in that country.

The companies expect the acquisition to close in the second half of 2026, subject to regulatory and other closing conditions, according to Kimberly-Clark's regulatory filings as summarized by metissue.com. The consideration is described as a combination of shares and cash, with the final transaction value subject to changes in Kimberly-Clark's share price.

Market Reaction

Kimberly-Clark shares rose more than 2.7% in early trading on the news, while Kenvue gained 2.3%, per metissue.com's report. By our calculation, the gap between the two moves was 0.4 percentage points (2.7% minus 2.3%), or roughly 17.4% larger in relative terms for Kimberly-Clark than for Kenvue on that comparison. This is a simple arithmetic comparison of the reported single-day moves and does not reflect an ongoing deal spread or imply any forward-looking signal about deal certainty.

Deal Rationale and Context

Kimberly-Clark announced the acquisition in November 2025. The transaction would add Kenvue brands including Listerine, Aveeno and Neutrogena, alongside a European portfolio spanning over-the-counter medicines, skin health and beauty, baby care, feminine hygiene and essential health products such as mouthwash and toothpaste, to Kimberly-Clark's existing lineup that includes Kleenex and Huggies, according to metissue.com.

Yahoo Finance's report on the Reuters coverage notes the combination would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark expects roughly $1.9 billion of annual cost synergies and $500 million of revenue synergies, while expecting to invest about $2.5 billion in cash to achieve the cost savings, according to the same report, which also notes that Kimberly-Clark's first-half 2026 organic sales rose only 1.2% and that the company subsequently lowered its full-year organic sales outlook. Interpretation, not a source conclusion: that slower organic growth helps explain why the acquisition — and the regulatory clearances it still requires — figures prominently in the company's growth plans.

Bottom Line

With the Commission's preliminary, or Phase I, deadline falling on September 29, Kimberly-Clark's reported preparation of concessions — potentially including asset sales — could, if formally submitted and accepted, allow the deal to clear without a more in-depth investigation that the reporting says could last roughly four months. The precise scope of any EU remedy remains unconfirmed: the European Commission declined to comment, and Kimberly-Clark and Kenvue did not respond to emailed requests for comment, so the shape of any eventual remedy package is still an open question heading into the deadline.